Non-vitamin K antagonist oral anticoagulants have provided an optimization of management of patients in the prevention of stroke in nonvalvular atrial fibrillation. The lack of an effective reversal agent has remained a challenge to these agents’ widespread utilization. Idarucizumab, a specific reversal agent for dabigatran, is approved in many countries including India. However, there is limited data for its use for Indian patients. We are reporting one of the cases of its use in India where it successfully reversed dabigatran prior to mechanical thrombectomy in acute ischemic stroke.
KirchhofPBenussiSKotechaDESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;(18):1609-1678.
2.
MartinezCKatholingAWallenhorstCTherapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC: A cohort study. Thromb Haemost. 2016;115(1):31-39.
3.
Praxbind® (idarucizumab) injection, for intravenous use, October 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Accessed July 17, 2019.
4.
GoriackoPYaghdjianVKoleilatISinnettMShuklaH.The use of idarucizumab for dabigatran reversal in clinical practice: A case series. Pharm Ther. 2017;42(11):699-703.
5.
VoskoMRBocksruckerCDrwiłaRReal-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: A series of 11 cases. J Thromb Thrombolysis. 2017;43(3):306-317.
6.
von WowernFBrizziMHolstJ.Reversal of the anticoagulation effects of dabigatran etexilate by idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke. EJCRIM2017;4: doi:10.12890/2017_000569
7.
GendronNFeral-PierssensALJurcisinIReal-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clin Case Rep. 2017;5(3):346-350.
8.
PikijaSSztrihaLKSebastian MutzenbachJGolaszewskiSMSellnerJ.Idarucizumab in dabigatran-treated patients with acute ischemic Stroke receiving alteplase: A Systematic review of the available evidence. CNS Drugs. 2017;31(9):747-757.
9.
KermerPEschenfelderCCDienerHCAntagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany: A national case collection. Int J Stroke. 2017;12(4):383-391.
10.
HankeyGJNorrvingBHackeWSteinerT.Management of acute stroke in patients taking novel oral anticoagulants. International Journal of Stroke. 2014;9(5):627-632.
